Nov 4, 6:46 AM ET
Versigent reported third-quarter 2026 net sales of $2.45 billion, up 7.2% year over year, but net income attributable to Versigent fell to $102 million from $109 million and diluted EPS fell to $1.41 from $1.54. The company raised the midpoint of its full-year net sales guidance and raised the upper end and midpoint of its free cash flow guidance, while tightening those ranges and its Adjusted EBITDA range.
- Q3 2026 net sales of $2,450 million, up 7.2% year over year; Adjusted Net Sales Growth of approximately 1%
- Diluted EPS of $1.41 vs. $1.54 a year earlier; Adjusted Diluted EPS of $1.91 vs. $1.81
- Full-year 2026 net sales guidance narrowed to $9,500-$9,600 million from $9,400-$9,600 million; free cash flow guidance raised to $275-$325 million from $200-$300 million
- Board declared a quarterly cash dividend of $0.13 per share, payable December 17, 2026
Read the filing on SEC.gov ↗
Aug 4, 6:59 AM ET
Versigent reported second-quarter 2026 net sales of $2.44 billion, up 10.8% from a year earlier, and net income attributable to Versigent of $118 million, up 10.3%. The company raised its full-year 2026 net sales guidance to $9.4 billion to $9.6 billion from $9.1 billion to $9.4 billion, reaffirmed its adjusted EBITDA and free cash flow guidance, and declared an inaugural quarterly dividend of $0.13 per share.
- Diluted EPS was $1.64 versus $1.51 a year earlier; adjusted diluted EPS was $1.92 versus $1.89.
- Adjusted EBITDA rose 24.8% to $272 million, with a margin of 11.1% versus 9.9%.
- Interest expense rose to $36 million from $1 million, mainly due to senior notes and a credit facility issued in the first quarter of 2026.
- The $0.13 dividend is payable September 18, 2026 to shareholders of record on September 4, 2026.
Read the filing on SEC.gov ↗
May 5, 4:07 PM ET
Versigent PLC, which was spun off from Aptiv PLC on April 1, 2026, reported first-quarter 2026 revenue of $2.2 billion, up 9%, but net income attributable to the company fell to $78 million from $95 million a year earlier. The company reaffirmed its full-year 2026 guidance and disclosed a dividend policy of $0.13 per share quarterly and a $250 million share repurchase program.
- Revenue of $2,212 million, up from $2,024 million; up about 3% excluding currency and commodity movements
- Net income attributable to Versigent of $78 million, versus $95 million; adjusted EBITDA of $203 million, versus $198 million, with margin of 9.2% versus 9.8%
- Free cash flow of $(30) million, versus $3 million a year earlier, including $26 million of separation costs
- Board approved a dividend policy of $0.13 per share quarterly (initial dividend not yet declared) and a $250 million share repurchase program with no expiration date; full-year 2026 guidance reaffirmed, including U.S. GAAP net income of $31
Read the filing on SEC.gov ↗
Apr 1, 5:18 PM ET
Aptiv PLC completed the spin-off of Versigent on April 1, 2026, distributing all Versigent ordinary shares to Aptiv shareholders, and Versigent began trading on the NYSE as VGNT that day. The company took on $1.35 billion in senior secured credit facilities and $1.6 billion in senior unsecured notes, with proceeds used to pay a dividend to Aptiv, and it appointed a new CEO and CFO effective with the spin-off.
- Aptiv shareholders of record on March 17, 2026 received one Versigent ordinary share for every three Aptiv shares held.
- Credit agreement includes a $500 million five-year term loan A, fully drawn March 27, 2026, and an $850 million five-year revolving credit facility.
- Cyprium Corporation and Cyprium Holdings Luxembourg issued $800 million of 6.125% notes due 2031 and $800 million of 6.375% notes due 2034 on March 18, 2026.
- Joseph T. Liotine was appointed Chief Executive Officer and Douglas R. Ostermann Chief Financial Officer, effective with the spin-off; Paul Meister became non-executive Chair.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.